2001
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Esteva F, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar A, Hortobagyi G. Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. The Oncologist 2001, 6: 133-146. PMID: 11306725, DOI: 10.1634/theoncologist.6-2-133.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHER-2/neu proteinAnthracycline/taxane combinationsDevelopment of anthracyclineAdvanced breast cancerHigh-dose chemotherapyPrimary breast cancerSingle-agent activityCombination chemotherapy treatmentsNovel biologic therapiesNovel treatment approachesMultidrug resistance inhibitorsTopoisomerase I inhibitorTaxane therapyBiologic therapyPalliative therapyTaxane combinationsProlong survivalTumor supressor geneChemotherapy treatmentTreatment approachesFluoropyrimidine analogsPatientsNeu protein
1996
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
Yu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diamandis E. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal Of Cancer 1996, 74: 1242-1247. PMID: 8883411, PMCID: PMC2075943, DOI: 10.1038/bjc.1996.523.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorProstate-specific antigenIGFBP-3IGF-IIBreast cancerS-phase fractionIGFBP-1Prognostic indicatorGrowth factorActive insulin-like growth factorsHER-2/neu proteinUnfavourable prognostic indicatorPrimary breast cancerEpidermal growth factor receptorSteroid hormone receptorsTumor tissue cytosolGrowth factor receptorIGF functionEstrogen receptorDNA ploidyPossible associationNeu proteinCancerTissue cytosolsHormone receptors
1992
A subdomain in the transmembrane domain is necessary for p185neu* activation.
Cao H, Bangalore L, Bormann BJ, Stern DF. A subdomain in the transmembrane domain is necessary for p185neu* activation. The EMBO Journal 1992, 11: 923-932. PMID: 1347745, PMCID: PMC556533, DOI: 10.1002/j.1460-2075.1992.tb05131.x.Peer-Reviewed Original ResearchMeSH Keywords3T3 CellsAmino Acid SequenceAnimalsBase SequenceBlotting, WesternCell MembraneElectrophoresis, Polyacrylamide GelErbB ReceptorsGliomaGlutamatesGlutamic AcidMiceMolecular Sequence DataMutagenesis, Site-DirectedNeuroblastomaPrecipitin TestsProtein-Tyrosine KinasesProto-Oncogene ProteinsRatsReceptor, ErbB-2Signal TransductionValineConceptsTransmembrane domainTyrosine kinase activityKinase activityElevated tyrosine kinase activitySite-directed mutagenesisSpecific amino acidsEpidermal growth factor receptorGlutamic acidGrowth factor receptorEGF receptorPrimary structureAmino acidsFactor receptorProteinSpecific interactionsActivationDomainMutagenesisReceptorsMolecular weightAcidNeu proteinP185neuHigh propensityRole
1991
TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
Cao H, Decker S, Stern DF. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. Oncogene 1991, 6: 705-11. PMID: 1675782.Peer-Reviewed Original ResearchConceptsImmune complex kinase assayReceptor-like proteinTyrosine kinase activityProtein kinase CThreonine phosphorylationThreonine residuesTransmembrane domainKinase assaysTyrosine phosphorylationKinase activityAntiphosphotyrosine antibodyIncubation of cellsKinase CPhosphorylationPoint mutationsProteinNeu/Neu proteinLabeling experimentsSerineP185PhosphotyrosineTPAOncogenicMutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply